TY - JOUR
T1 - Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission
AU - Bodey, Gerald P.
AU - Rodriguez, Victorio
AU - Cabanillas, Fernando
AU - Freireich, Emil J.
N1 - Funding Information:
From the Department of Developmental Therapeutics, The University of Texas System Cancer Center M. 0. Anderson Hospital and Tumor Institute, Houston, Texas. This paper was supported in part by Contract NOI-CM-43801 and Grant CA 05831 from the National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Maryland. Requests for reprints should be addressed to Dr. Gerald P. Bodey, The University of Texas System Cancer Center, Texas Medical Center, Houston, Texas 77930. Manuscript accepted lune X5,1978.
PY - 1979/1
Y1 - 1979/1
N2 - Fifty-eight patients with malignant lymphoma were randomly allocated to receive three courses of chemotherapy to induce remission with CHOP-Bleo on the protected environment-prophylactic antibiotic (PEPA) program (30 patients) or as controls (28 patients). The complete remission rate for all patients was 74 per cent, for patients with diffuse histiocytic lymphoma 78 per cent and for patients with nodular poorly differentiated lymphocytic lymphoma 65 per cent. There were no significant differences in response rates and duration of responses between those on the PEPA program and control patients. The frequency of infection was significantly lower among the patients on the PEPA program, and dosage escalation of the chemotherapeutic agents was accomplished more often among these patients. Dosage escalation did not increase the complete remission rate, but it did reduce the relapse rate and significantly reduced the fatality rate. The duration of remission and survival was significantly longer for those patients who received dosage escalation.
AB - Fifty-eight patients with malignant lymphoma were randomly allocated to receive three courses of chemotherapy to induce remission with CHOP-Bleo on the protected environment-prophylactic antibiotic (PEPA) program (30 patients) or as controls (28 patients). The complete remission rate for all patients was 74 per cent, for patients with diffuse histiocytic lymphoma 78 per cent and for patients with nodular poorly differentiated lymphocytic lymphoma 65 per cent. There were no significant differences in response rates and duration of responses between those on the PEPA program and control patients. The frequency of infection was significantly lower among the patients on the PEPA program, and dosage escalation of the chemotherapeutic agents was accomplished more often among these patients. Dosage escalation did not increase the complete remission rate, but it did reduce the relapse rate and significantly reduced the fatality rate. The duration of remission and survival was significantly longer for those patients who received dosage escalation.
UR - http://www.scopus.com/inward/record.url?scp=0018743543&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018743543&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(79)90485-6
DO - 10.1016/0002-9343(79)90485-6
M3 - Article
C2 - 84532
AN - SCOPUS:0018743543
SN - 0002-9343
VL - 66
SP - 74
EP - 81
JO - The American journal of medicine
JF - The American journal of medicine
IS - 1
ER -